ESC 365 - Novel direct effects of SGLT2 inhibitor, Canagliflozin, on myocardial redox state in humans.

ESC Premium Access

Novel direct effects of SGLT2 inhibitor, Canagliflozin, on myocardial redox state in humans.

Session: Poster Session 7 - Pharmacotherapy of diabetes: from bench to bedside

Topic: Antidiabetic Pharmacotherapy

Speaker: Doctor H. Kondo (Yufu City, JP)

Event: ESC Congress 2019

Congress Presentation

Add to my library

About the speaker

Doctor Hidekazu Kondo

Hasama Campus - Faculty of Medicine, Oita University, Yufu City (Japan)

0 follower

6 more presentations in this session

Circulating microparticules of patients with coronary artery disease up-regulate the expression of sodium-glucose cotransporters 1 and 2 in coronary artery endothelial cells: role of angiotensin II

Speaker: Doctor S. Park (Illkirch, FR)

Cardiovascular outcomes of new anti-diabetic agents - A meta-analysis of randomized controlled trials

Speaker: Doctor C. Parco (Ibbenbueren, DE)

Early glycemic changes after initiation of oral anti-diabetic medication and risk of major adverse cardiovascular events: results from a large primary care population of patients with type 2 diabetes

Speaker: Mr J. Ghouse (Copenhagen, DK)

Empagliflozin reduces the total burden of first and recurrent hospitalisations in patients with type 2 diabetes and established cardiovascular disease

Speaker: Professor D. McGuire (Dallas, US)

The effect of semaglutide once weekly on MACE and blood pressure by race and ethnicity: SUSTAIN 6 post hoc analysis

Speaker: Professor C. Desouza (Omaha, US)

Access the full session

Poster Session 7 - Pharmacotherapy of diabetes: from bench to bedside

Speakers: Doctor H. Kondo, Doctor S. Park, Doctor C. Parco, Mr J. Ghouse, Professor D. McGuire...

About the event

ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources